Päffikon (SZ) Switzerland 19th of April 2021: Saiba Animal Health reported today that the rights for its two lead assets, SAH001 (HypoCat) and SAH003 (CAD vaccine) have been transferred from Benchmark Animal Health to a leading global Animal Health Company.

In 2014 and in 2015, Saiba Animal Heath (HypoPet AG) and Benchmark Holdings PLC entered into separate licensing agreements for the development and commercialization of vaccines for cat allergy (SAH001/HypoCat) and Canine Atopic Dermatitis (SAH003). In Benchmark’s 2020 annual report, the group announced that it has exited from its non-core, non-aquaculture related vaccine development collaborations and divested its companion animal vaccine development programs and GMP vaccine manufacture facility in Essex. The rights to Saiba’s HypoCat and CAD companion animal vaccines and future benefits from their successful development have now been transferred to a third-party.

Dr Gary T. Jennings, CEO of Saiba Animal Health AG stated, “Benchmark’s transfer of rights to a third party, a leading global animal health company, represents a unique and exciting opportunity for Saiba Animal Health. Our new partner, who has recognized the potential of these projects to address major unmet veterinary needs, has the development and commercial strength to help us effectively realize the prospects of our innovative product candidates. We have made important progress with both cat and dog programs and look forward to continued efforts in this new collaboration”.

For further information, please contact

Saiba Animal Health AG
CH-8808 Pfäffikon (SZ),
Switzerland
Gary Jennings, PhD
CEO
gary.jennings@saiba-animalhealth.com